KROS Q4 2021 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M

Gross Profit

$20M98.5% margin

Operating Income

-$5M-24.3% margin

Net Income

-$7M-34.7% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$255M

Total Liabilities

$12M

Stockholders' Equity

$243M

Cash & Equivalents

$230M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$0	—
Gross Profit	$20M	$0	—
Operating Income	-$5M	-$13M	+63.4%
Net Income	-$7M	-$11M	+35.0%

Revenue Segments

License

$20M100%